Neurological conditions

Epilepsy: symptoms and diagnosis

An overview of epilepsy, including seizure types, associated risks and diagnosis.…

Multiple sclerosis: disease-modifying therapies

An overview of the available evidence for each disease-modifying therapy for multiple sclerosis, when they are indicated, as well as each stage of patient care.…

Racial and ethnic disparities in mental health care

An overview of evident racial inequalities in mental health treatments across all ages, as well as discussion on how pharmacists can challenge and/or prevent this imbalance.…

Headache: a visual guide

Headache is among the most common neurological reasons for A&E attendance, but most cases can be treated in primary care. This infographic provides a visual overview of the main types of headache.…

Pharmacist-led atrial fibrillation case finding programme prevents an estimated 90 strokes

A pharmacist-led programme to identify patients with atrial fibrillation may have prevented up to 90 AF-related strokes across 23 clinical commissioning group areas, NHS England has said.…

One in ten hospital trusts have been asked to approve unlicensed cannabis-based medicinal prescriptions

Around 10% of hospital trusts have received requests for prescriptions of unlicensed cannabis-based medical products.…

Siponimod now recommended for patients with secondary progressive MS

Updated draft guidance from the National Institute for Health and Care Excellence has recommended siponimod for the treatment of secondary progressive multiple sclerosis.…

Cannabis-based Epidyolex approved for NHS use in Scotland

Epidyolex, a cannabidiol medicine for severe epilepsy in children, has been approved for use on the NHS in Scotland.…

New pharmacist-led network is sharing best practice in medicines for neurodiverse patients

As pharmacy professionals, we work across a wide range of sectors in various locations, within different clinical specialities and teams to deliver best practice in medicines optimisation. But to do this in a truly person-centred way, we need to keep the patient experience in mind through the …

Anticholinergic medications increase risk of mild cognitive impairment, study suggests

Anticholinergic medicines more than double the risk of mild cognitive impairment and accelerated memory and language decline in those predisposed to Alzheimer’s disease, a study in Neurology has suggested.…